Open AccessSafety and Efficacy of Intravitreal Risuteganib for Non-Exudative AMD: A Multicenter, Phase 2a, Randomized, Clinical Trial
Author(s) -
David S. Boyer,
Víctor H. González,
Derek Kunimoto,
Raj K. Maturi,
Richard H. Roe,
Michael Singer,
Samantha Xavier,
Julie Kornfield,
Baruch D. Kuppermann,
Hugo Quiróz-Mercado,
Janine Aubel,
Hampar Karageozian,
John Y. Park,
Vicken Karageozian,
Lisa Karageozian,
Melvin Sarayba,
Peter Kaiser
Publication year - 2021
Publication title -
ophthalmic surgery, lasers and imaging retina
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.676
H-Index - 30
eISSN - 2325-8179
pISSN - 2325-8160
DOI - 10.3928/23258160-20210528-05
Subject(s) - medicine , clinical endpoint , diabetic retinopathy , adverse effect , macular degeneration , randomized controlled trial , ophthalmology , clinical trial , visual acuity , prospective cohort study , surgery , diabetes mellitus , endocrinology
To evaluate the safety and efficacy of 1.0 mg risuteganib in subjects with nonexudative age-related macular degeneration (AMD).